Zhejiang Anglikang Pharmaceutical Co. Ltd.

Zhejiang Anglikang Pharmaceutical Co. saw a notable increase in its stock today, contrasting with the broader market's modest gains. The company reported a significant net profit growth for the nine months ending March 26, alongside a decrease in raw material costs and a stable valuation.

Zhejiang Anglikang Pharmaceutical Co. saw a significant rise in its stock today, contrasting with a broader market decline. Over the past week, it has outperformed the market, although it has faced volatility in the past month and a decline over the past year. The company maintains a fair valuation and offers a modest dividend yield.

Zhejiang Anglikang Pharmaceutical Co. faced a significant stock decline on June 8, 2026, reaching an intraday low. Despite a strong annual return, year-to-date performance has decreased. Financial metrics show robust profit growth, but the stock's valuation remains high within the pharmaceuticals and biotechnology sector.

Zhejiang Anglikang Pharmaceutical Co. faced notable market activity on May 25, 2026, with a significant stock decline. Over the past week, the company has experienced a downturn, although it boasts an impressive annual return. Financial metrics indicate mixed performance, with modest sales growth and a declining operating profit.

Zhejiang Anglikang Pharmaceutical Co. saw notable stock activity on May 22, 2026, with a significant decline. Despite recent challenges, the company has achieved impressive annual returns and strong net profit growth, although long-term sales growth remains modest. It continues to offer a high dividend yield to shareholders.

Zhejiang Anglikang Pharmaceutical Co. saw a notable increase in its stock price, reaching an intraday high of CNY 45.65. Over the past year, the company has achieved impressive returns, significantly outpacing the China Shanghai Composite, despite facing a slight decline in profits and maintaining a relatively high valuation.

Zhejiang Anglikang Pharmaceutical Co. has recently experienced an evaluation adjustment, highlighting shifts in its stock assessment. While the company reported positive quarterly financial performance, long-term growth indicators reveal challenges, including declining operating profit and fluctuating net sales, alongside a notable stock return and modest dividend yield.

Zhejiang Anglikang Pharmaceutical Co. has seen a notable rise in stock performance, reaching an intraday high. The company reported a significant increase in net sales and impressive quarterly growth in pre-tax and net profits. Despite challenges in long-term growth, its current performance reflects a strong market position.